11β-Hydroxysteroid dehydrogenase Type 1 as a novel therapeutic target in metabolic and neurodegenerative disease

By Walker Brian R   Seckl Jonathan R  

Expert Opinion on Therapeutic Targets, Vol. 7, Iss. 6, 2003-12 ,pp. : 771-783

Informa Healthcare

Access to resources Recommend Favorite

Tissue-specific Cushing's syndrome uncovers a new target in treating the metabolic syndrome – 11β-hydroxysteroid dehydrogenase type 1

By Stewart Paul M  

Clinical Medicine, Vol. 5, Iss. 2, 2005-03 ,pp. : 142-146

Royal College Of Physicians

Access to resources Recommend Favorite

11β-Hydroxysteroid dehydrogenase type 1 inhibitors as therapeutic agents

By Webster Scott Peter   Pallin Thomas David  

Expert Opinion on Therapeutic Patents, Vol. 17, Iss. 12, 2007-12 ,pp. : 1407-1422

Informa Healthcare

Access to resources Recommend Favorite

Type 1 11 &bgr;-hydroxysteroid Dehydrogenase as Universal Drug Target in Metabolic Diseases?

By  

Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders), Vol. 6, Iss. 3, 2006-09 ,pp. : 259-269

Bentham Science Publishers

Access to resources Recommend Favorite

11&bgr;-Hydroxysteroid Dehydrogenase Type 1 Inhibitors as Promising Therapeutic Drugs for Diabetes: Status and Development

By  

Current Medicinal Chemistry, Vol. 17, Iss. 5, 2010-02 ,pp. : 412-422

Bentham Science Publishers

Access to resources Recommend Favorite